Etienne Flamant

Mr. Etienne Flamant

Duke University School of Medicine

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2015 in Protocol Exchange
Verified
Journal Article
Open access
USUrsula Stochaj
Ursula Stochaj
MKMohamed Kodiha
Mohamed Kodiha
BPBrigitte Pié
Brigitte Pié
YWYi Meng Wang
Yi Meng Wang
EFEtienne Flamant
Etienne Flamant
ECEllis Cooper
Ellis Cooper
Mitochondria are the major energy providers in most mammalian cells. Mitochondrial dysfunction has been linked to multiple diseases and pathophysiologies, including a growing number of neurodegenerative disorders. Moreover, as key regulators of cell death, mitochondria are also prime targets for cancer research and at the center of drug development. The mitochondrial membrane potential is essential for ATP production and an important parameter to assess the functional state of these organelles. As MitoTracker® dyes concentrate in active mitochondria, they are ideal tools to evaluate mitochondrial function. We have developed a simple, fast and reliable protocol that measures MitoTracker® signals associated with mitochondria. Our protocol was successfully applied to assess changes in the mitochondrial membrane potential in diverse cell types from different organisms. The method developed by us provides a powerful tool for mitochondrial research and can be easily adapted for drug screening.

11 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Jason SomarelliJason Somarelli
Jason Somarelli
GRGabrielle Rupprecht
Gabrielle Rupprecht
Erdem AltunelErdem Altunel
Erdem Altunel
EFEtienne Flamant
Etienne Flamant
SRSneha Rao
Sneha Rao
DHDavid S. Hsu
David S. Hsu
Background: Osteosarcoma is a rare but aggressive bone cancer that occurs primarily in children. Like other rare cancers, treatment advances for osteosarcoma have stagnated, with little improvement in survival for the past several decades. Developing new treatments has been hampered by extensive genomic heterogeneity and limited access to patient samples to study the biology of this complex disease. Methods: To overcome these barriers, we combined the power of comparative oncology with patient-derived models of cancer and high-throughput chemical screens in a cross-species drug discovery pipeline. Results: Coupling in vitro high-throughput drug screens on low-passage and established cell lines with in vivo validation in patient-derived xenografts we identify the proteasome and CRM1 nuclear export pathways as therapeutic sensitivities in osteosarcoma, with dual inhibition of these pathways inducing synergistic cytotoxicity. Conclusions: These collective efforts provide an experimental framework and set of new tools for osteosarcoma and other rare cancers to identify and study new therapeutic vulnerabilities.

1 February 2021 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
EBElshaday S. Belay
Elshaday S. Belay
JOJeffrey O’dOnnell
Jeffrey O’dOnnell
EFEtienne Flamant
Etienne Flamant
ZHZoe Hinton
Zoe Hinton
CKChristopher S. Klifto
Christopher S. Klifto
OAOke Anakwenze
Oke Anakwenze

12 March 2022 in Seminars in Arthroplasty: JSES
Verified
Journal Article
Closed access
JWJohn R. Wickman
John R. Wickman
KCKevin J. Cronin
Kevin J. Cronin
DGDaniel E. Goltz
Daniel E. Goltz
JLJay Levin
Jay Levin
EFEtienne Flamant
Etienne Flamant
CKChristopher S. Klifto
Christopher S. Klifto

30 August 2018 in PeerJ
Verified
Journal Article
Open access
PDF file
MKMohamed Kodiha
Mohamed Kodiha
EFEtienne Flamant
Etienne Flamant
YWYi Meng Wang
Yi Meng Wang
USUrsula Stochaj
Ursula Stochaj
Background Under aerobic growth conditions, mitochondria are the major producers of cellular ATP and crucial for the proper performance of organs and tissues. This applies especially to cells with high energy demand, such as the renal proximal tubule epithelium. Mitochondrial dysfunction contributes to the pathology of human health conditions, including various kidney diseases. The improvement of mitochondrial function ameliorates some of these pathologies. This can potentially be achieved with pharmacological compounds. For example, long-term treatment with activators of 5′-AMP activated kinase (AMPK) enhances mitochondrial biogenesis. However, pharmacological damage control during acute cell injury requires that the short-term effects of these compounds and the impact on healthy cells are also understood. It was our objective to define the changes elicited by established modulators of AMPK activity in healthy renal proximal tubule cells. Methods Our work combines confocal microscopy with quantitative image analysis, 3D image reconstruction and Western blotting to provide novel insights into the biology of mitochondria. Specifically, we evaluated the effects of pharmacological AMPK modulators (compound C, AICAR, phenformin, resveratrol) on mitochondrial polarization, morphology and heterogeneity. Microscopic studies generated information at the single cell and subcellular levels. Our research focused on LLC-PK1 cells that are derived from the renal proximal tubule. Mitochondrial heterogeneity was also examined in MCF7 breast cancer cells. Results Pharmacological agents that affect AMPK activity in renal proximal tubule cells can alter mitochondrial organization and the electrochemical potential across the inner mitochondrial membrane. These changes were compound-specific. Short-term incubation with the AMPK inhibitor compound C caused mitochondrial hyperpolarization. This was accompanied by mitochondrial fragmentation. By contrast, AMPK activators AICAR, phenformin and resveratrol had little impact. We further show that the biological properties of mitochondria are determined by their subcellular location. Mitochondria at the cell periphery displayed higher MitoTracker/Tom70 values as compared to organelles located in the vicinity of the nucleus. This was not limited to renal proximal tubule cells, but also observed in MCF7 cells. Pharmacological AMPK modulators altered these location-dependent properties in a compound-specific fashion. While the region-dependent differences were enhanced with phenformin, they were ameliorated by resveratrol. Discussion We evaluated the rapid changes in mitochondrial characteristics that are induced by pharmacological AMPK modulators. Our research supports the concept that pharmacological agents that target AMPK can rearrange mitochondrial networks at the single cell level. Collectively, these insights are relevant to the development of proper strategies for the short-term adjustment of mitochondrial performance.

1 January 2021 in JSES International
Verified
Journal Article
Open access
EBElshaday S. Belay
Elshaday S. Belay
EFEtienne Flamant
Etienne Flamant
BSBarrie Sugarman
Barrie Sugarman
DGDaniel E. Goltz
Daniel E. Goltz
CKChristopher S. Klifto
Christopher S. Klifto
OAOke Anakwenze
Oke Anakwenze
Identifying areas of excess cost for shoulder arthroplasty patients can play a role in effective health care spending. The purpose of this study was to assess the utility of postoperative complete blood count (CBC) testing after total shoulder arthroplasty (TSA) and identify which patients benefit from routine CBC testing. We performed a retrospective review of a cohort of patients who underwent primary TSA from January 2018 through January 2019. All patients in this cohort received tranexamic acid. Patient demographic characteristics and patient-specific risk factors such as American Society of Anesthesiologists score, Elixhauser index, body mass index, smoking status, and coagulopathy history were obtained. Perioperative values including length of surgery, preoperative and postoperative hemoglobin (Hgb) levels, and need for transfusion were also obtained. This study included 387 TSA patients in the final analysis. Comparison between the cohort requiring transfusion and the cohort undergoing no intervention revealed no statistically significant differences in age, sex, body mass index, American Society of Anesthesiologists score, or Elixhauser index. The group receiving transfusions was found to have significantly lower levels of preoperative Hgb (11.3 g/dL) and postoperative Hgb (8.1 g/dL) (P < .0001). Additionally, the percentages of patients with abnormal preoperative Hgb levels ( 12 mg/dL and first postoperative Hgb levels > 9 mg/dL. This translates to potential health care cost savings and improves current evidence-based perioperative management in shoulder arthroplasty.